Raffaella Di Micco is a researcher specializing in chromatin structure alterations and DNA damage response (DDR) in hematopoietic system senescence. She obtained her degree in Medical Biotechnology from the University of Naples Federico II and her PhD in Molecular Medicine from the IFOM Institute (FIRC Institute of Molecular Oncology) in Milan. Subsequently, she conducted postdoctoral research at the New York University School of Medicine in New York. Currently, she leads a laboratory at the Telethon Institute for Gene Therapy (SR-TIGET) within the San Raffaele Hospital in Milan, where she conducts advanced research on epigenetic regulators in the development of leukemia and cellular stress responses in hematopoietic stem cells in gene therapy contexts. Her publications include significant studies on oncogene-induced senescence as a response to DNA damage, epigenetic reader-dependent regulation of stem cell functionality maintenance, and the role of DDR responses following genetic engineering approaches, such as the well-known CRISPR technology. Throughout her career, Dr. Di Micco has received numerous prestigious awards, including fellowships and grants from the European Molecular Biology Organization (EMBO), Human Frontier Science Program (HFSP), and the New York Stem Cell Foundation (NYSCF), and is an active member of important organizations such as the American Association for Cancer Research (AACR), the International Society for Stem Cell Research (ISSCR), the European Society of Gene and Cell Therapy (ESCGT), and the European Hematology Association (EHA). Prof. Di Micco’s research activities have received significant funding from various Italian and international agencies and are currently supported by the European Research Council's “ReviveSTEM” project and the New York Stem Cell Robertson Investigator Award. Her multidisciplinary research group integrates basic biology with translational and applied research, aiming to advance the understanding of mechanisms regulating blood-related diseases linked to aging to develop innovative therapies.

Twitter: @DiMiccoLab
Linkedin: Raffaella Di Micco
Pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=Di+Micco+Raffaella